JP5401463B2 - 新規な結晶性ジフェニルアゼチジノン水和物、これらの化合物を含有する薬剤およびそれらの使用 - Google Patents

新規な結晶性ジフェニルアゼチジノン水和物、これらの化合物を含有する薬剤およびそれらの使用 Download PDF

Info

Publication number
JP5401463B2
JP5401463B2 JP2010533467A JP2010533467A JP5401463B2 JP 5401463 B2 JP5401463 B2 JP 5401463B2 JP 2010533467 A JP2010533467 A JP 2010533467A JP 2010533467 A JP2010533467 A JP 2010533467A JP 5401463 B2 JP5401463 B2 JP 5401463B2
Authority
JP
Japan
Prior art keywords
formula
compound
administered
combination
crystalline hydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010533467A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011503127A (ja
JP2011503127A5 (enExample
Inventor
テーオドール・アンドレーアス・ヴォルマン
レジーナ・デューフィー
フランク・クルマン
Original Assignee
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40386121&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5401463(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング filed Critical サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング
Publication of JP2011503127A publication Critical patent/JP2011503127A/ja
Publication of JP2011503127A5 publication Critical patent/JP2011503127A5/ja
Application granted granted Critical
Publication of JP5401463B2 publication Critical patent/JP5401463B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2010533467A 2007-11-13 2008-11-06 新規な結晶性ジフェニルアゼチジノン水和物、これらの化合物を含有する薬剤およびそれらの使用 Expired - Fee Related JP5401463B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE102007054497A DE102007054497B3 (de) 2007-11-13 2007-11-13 Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
DE102007054497.0 2007-11-13
US99025507P 2007-11-26 2007-11-26
US60/990,255 2007-11-26
PCT/EP2008/009323 WO2009062619A1 (de) 2007-11-13 2008-11-06 Neue kristalline diphenylazetidinonhydrate, diese verbindungen enthaltende arzneimittel und deren verwendung

Publications (3)

Publication Number Publication Date
JP2011503127A JP2011503127A (ja) 2011-01-27
JP2011503127A5 JP2011503127A5 (enExample) 2011-12-22
JP5401463B2 true JP5401463B2 (ja) 2014-01-29

Family

ID=40386121

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010533467A Expired - Fee Related JP5401463B2 (ja) 2007-11-13 2008-11-06 新規な結晶性ジフェニルアゼチジノン水和物、これらの化合物を含有する薬剤およびそれらの使用

Country Status (11)

Country Link
US (1) US8003636B2 (enExample)
EP (1) EP2220040B1 (enExample)
JP (1) JP5401463B2 (enExample)
AR (1) AR069305A1 (enExample)
CL (1) CL2008003358A1 (enExample)
DE (2) DE102007054497B3 (enExample)
PA (1) PA8803701A1 (enExample)
PE (1) PE20091165A1 (enExample)
TW (1) TW200936566A (enExample)
UY (1) UY31469A1 (enExample)
WO (1) WO2009062619A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8486926B2 (en) * 2006-11-17 2013-07-16 Harbor Therapeutics, Inc. Steroid tetrol solid state forms
US20080319221A1 (en) * 2007-06-22 2008-12-25 Bernd Junker Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids
WO2009100258A1 (en) * 2008-02-05 2009-08-13 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical solid state forms
KR101545300B1 (ko) 2008-04-03 2015-08-18 하버 바이오사이언시즈 인코포레이티드 고체 형태의 약제
EP2937348B1 (en) * 2012-12-22 2021-09-08 Kbp Biosciences Pte. Ltd. Process for the preparation of a compound used as mineralocorticoid receptor antagonist
US10080759B2 (en) 2014-01-22 2018-09-25 Duke University Methods of treating pruritus
WO2015112588A1 (en) 2014-01-22 2015-07-30 Biomimetix Jv, Llc Methods of treating skin disorders

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0124317B1 (en) * 1983-04-27 1990-04-11 Ici Americas Inc. Proline derivatives
FR2663336B1 (fr) 1990-06-18 1992-09-04 Adir Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2713225B1 (fr) 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) * 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
DE69621952T2 (de) 1995-10-31 2003-01-16 Schering Corp., Kenilworth Zuckersubstituierte 2-azetidinone, verwendbar als hypocholesterdenische arzneimittel
CZ220498A3 (cs) 1996-01-17 1998-11-11 Novo Nordisk A/S Deriváty 1,2,4-thiadiazinu a 1,4-thiazinu, příprava a použití
US6225310B1 (en) * 1996-01-17 2001-05-01 Novo Nordisk A/S Fused 1,2,4-thiadiazine derivatives, their preparation and use
US5739321A (en) 1996-05-31 1998-04-14 Schering Corporation 3-hydroxy γ-lactone based enantionselective synthesis of azetidinones
US6268343B1 (en) * 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
JP3149958B2 (ja) 1996-08-30 2001-03-26 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ―１誘導体
US5756470A (en) * 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
DE69723869T2 (de) 1996-12-31 2004-04-22 Dr. Reddy's Laboratories Ltd. Heterozyklische verbindungen, verfahren zu ihrer herstellung, pharmazeutische zusammensetzungen die diese enthalten und ihre anwendung in der behandlung von diabetis und verwandten krankheiten
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
EP1000066A1 (en) 1997-07-16 2000-05-17 Novo Nordisk A/S Fused 1,2,4-thiadiazine derivatives, their preparation and use
CO4970713A1 (es) 1997-09-19 2000-11-07 Sanofi Synthelabo Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
AU756965B2 (en) 1998-03-12 2003-01-30 Microbial Chemistry Research Foundation Benzofurylpyrone derivatives
US6221897B1 (en) 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19845405C2 (de) 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
WO2000034331A2 (en) 1998-12-07 2000-06-15 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Analogues of glp-1
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
DE19916108C1 (de) 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
AR023463A1 (es) 1999-04-16 2002-09-04 Schering Corp Uso de compuestos de azetidinona
PT1177176E (pt) 1999-04-28 2006-08-31 Aventis Pharma Gmbh Derivados de acidos triarilicos como ligandos de receptores ppar.
IL145922A0 (en) 1999-04-28 2002-07-25 Aventis Pharma Gmbh Di-aryl acid derivatives as ppar receptor ligands
GB9911863D0 (en) 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
CA2376919C (en) 1999-06-18 2008-11-04 Merck & Co., Inc. Arylthiazolidinedione and aryloxazolidinedione derivatives
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
DK1204654T3 (da) 1999-07-29 2003-11-17 Lilly Co Eli Benzofurylpiperaziner og benzofurylhomopiperaziner: Serotonin agonister
BR0013727A (pt) 1999-09-01 2002-05-07 Aventis Pharma Gmbh Derivados de sulfonilcarboxamida, processo para sua preparação e seu uso como medicamento
PE20011010A1 (es) 1999-12-02 2001-10-18 Glaxo Group Ltd Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano
JP2003523396A (ja) 2000-02-25 2003-08-05 ノボ ノルディスク アクティーゼルスカブ ベータ細胞変性の抑制
PT1277736E (pt) 2000-04-28 2007-10-12 Asahi Kasei Pharma Corp Novos compostos bicíclicos
JP2004507456A (ja) 2000-05-11 2004-03-11 ブリストル−マイヤーズ　スクイブ　カンパニー 成長ホルモン分泌促進薬として有用なテトラヒドロイソキノリン類縁体
SE0001899D0 (sv) 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
JP2004513076A (ja) * 2000-07-25 2004-04-30 メルク　エンド　カムパニー　インコーポレーテッド 糖尿病治療で有用なｎ−置換インドール類
HUP0004741A2 (hu) 2000-11-28 2002-12-28 Sanofi-Synthelabo Kémiai eljárás tiazolszármazékok előállítására és új intermedier
HRP20030501A2 (en) 2000-12-21 2005-04-30 Aventis Pharma Deutschland Gmbh Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
IL156552A0 (en) * 2000-12-21 2004-01-04 Aventis Pharma Gmbh Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
HUP0401081A3 (en) * 2000-12-21 2010-06-28 Sanofi Aventis Deutschland Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and their use
TWI291957B (en) 2001-02-23 2008-01-01 Kotobuki Pharmaceutical Co Ltd Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same
GB0113233D0 (en) 2001-05-31 2001-07-25 Glaxo Group Ltd Chemical compounds
DE10139416A1 (de) 2001-08-17 2003-03-06 Aventis Pharma Gmbh Aminoalkyl substituierte aromatische Bicyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
JP4436129B2 (ja) 2001-08-31 2010-03-24 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ジアリールシクロアルキル誘導体、その製造法及びｐｐａｒ−活性剤としてのその使用
US6884812B2 (en) * 2001-08-31 2005-04-26 Aventis Pharma Deutschland Gmbh Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals
DE10215907A1 (de) 2002-04-11 2003-11-06 Aventis Pharma Gmbh Acyl-4-carboxyphenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung
JPWO2003097064A1 (ja) 2002-05-17 2005-09-15 協和醗酵工業株式会社 糖尿病治療剤
US7176193B2 (en) * 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
DE10227508A1 (de) 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Säuregruppen-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE10227507A1 (de) 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Kationisch substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE10227506A1 (de) 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Ringsubstituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US7176194B2 (en) * 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
US7671047B2 (en) * 2002-06-19 2010-03-02 Sanofi-Aventis Deutschland Gmbh Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
GB0215579D0 (en) * 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
ATE452879T1 (de) 2002-07-12 2010-01-15 Sanofi Aventis Deutschland Heterozyklisch substituierte benzoylharnstoffe, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE10314610A1 (de) * 2003-04-01 2004-11-04 Aventis Pharma Deutschland Gmbh Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung
US20060200534A1 (en) 2003-04-25 2006-09-07 Takahiro Nagai Multi-medium information sharing system
JP2005015434A (ja) 2003-06-27 2005-01-20 Kotobuki Seiyaku Kk 血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤
KR20060052792A (ko) 2003-07-09 2006-05-19 포비스 메디-테크 인코포레이티드 신규 화합물 및 스테롤 및/또는 스탄올 및 콜레스테롤생합성 억제제를 포함하는 조성물 및 다양한 질병 및증상을 치료 또는 예방하기 위한 이들의 용도
EP1644411A2 (en) 2003-07-11 2006-04-12 Novo Nordisk A/S Stabilised insulin compositions
US20070072812A1 (en) 2003-08-25 2007-03-29 Microbia, Inc. Quaternary salt derivatives of 1,4-diphenylazetidin-2-ones
US20070161577A1 (en) 2003-08-28 2007-07-12 Martinez Eduardo J Tethered dimers and trimers of 1,4-diphenylazetidin-2-ones
KR101241862B1 (ko) 2003-09-19 2013-03-13 노보 노르디스크 에이/에스 신규 ｇｌｐ-1 유도체
EP1522541A1 (en) 2003-10-07 2005-04-13 Lipideon Biotechnology AG Novel hypocholesterolemic compounds
US20070135357A1 (en) 2003-10-30 2007-06-14 Sings Heather L Anti-hypercholesterolemic compounds
WO2005042692A2 (en) 2003-10-31 2005-05-12 Forbes Medi-Tech Inc. A method of inhibiting the expression of genes which mediate cellular cholesterol influx in animal cells and inhibiting the production of proteins resulting from the expression of such genes using cholesterol absorption inhibitors
DE602004008100T2 (de) 2003-11-10 2008-04-30 Microbia Inc., Cambridge 4-biarylyl-1-phenylazetidin-2-one
CA2550215A1 (en) 2003-12-23 2005-07-07 Astrazeneca Ab Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity
GB0329778D0 (en) 2003-12-23 2004-01-28 Astrazeneca Ab Chemical compounds
WO2005062824A2 (en) 2003-12-23 2005-07-14 Merck & Co., Inc. Anti-hypercholesterolemic compounds
CA2551639A1 (en) 2004-01-06 2005-07-28 Janssen Pharmaceutica N.V. (3-oxo-3, 4-dihydro-quinoxalin-2-yl-amino) -benzamide derivatives and related compound as glycogen phosphorylase inhibitors for the treatment of diabetes and obesity
DE102004006325A1 (de) 2004-02-10 2005-08-25 Bayer Healthcare Ag Tetrahydrobenzo[d]azepin-2-on-Derivate und ihre Verwendung
JP4846709B2 (ja) 2004-03-10 2011-12-28 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ５員複素環で置換されているｍｔｐ阻害性アリールピペリジン若しくはピペラジン
JPWO2005097738A1 (ja) 2004-04-06 2008-02-28 大日本住友製薬株式会社 新規スルホンアミド誘導体
EP1734930A2 (en) 2004-04-09 2006-12-27 Smithkline Beecham Corporation Low dose pharmaceutical products
DE102004025072A1 (de) * 2004-05-21 2005-12-15 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Diphenyl-azetidinon-Derivaten
FR2871463B1 (fr) 2004-06-11 2006-09-22 Merck Sante Soc Par Actions Si Derives a structure aroyl-o-piperidine, leurs procedes de preparation, les compositions pharmaceutiques qui les contiennent et leurs applications en therapeutique
JP2008504266A (ja) 2004-06-24 2008-02-14 イーライ リリー アンド カンパニー 異脂肪血症を治療するための化合物及び方法
WO2006017257A2 (en) 2004-07-12 2006-02-16 Phenomix Corporation Azetidinone derivatives
FR2873368B1 (fr) 2004-07-26 2008-01-04 Merck Sante Soc Par Actions Si Derives de guanidine et leurs utilisations en therapeutique
FR2873694B1 (fr) 2004-07-27 2006-12-08 Merck Sante Soc Par Actions Si Nouveaux aza-indoles inhibiteurs de la mtp et apob
MX2007002689A (es) 2004-09-11 2007-05-16 Sanofi Aventis Deutschland 7-azaindoles y su uso como agonistas de ppar.
EP2330126B1 (en) 2004-10-07 2015-12-23 Novo Nordisk A/S Protracted exendin-4 compounds
JP2008515856A (ja) 2004-10-07 2008-05-15 ノボ ノルディスク アクティーゼルスカブ 遅延性ｇｌｐ−１化合物
WO2006045564A1 (en) 2004-10-22 2006-05-04 Smithkline Beecham Corporation Xanthine derivatives with hm74a receptor activity
JP2008517029A (ja) 2004-10-22 2008-05-22 スミスクライン・ビーチャム・コーポレイション Ｈｍ７４ａ受容体活性を有するキサンチン誘導体
JPWO2006059744A1 (ja) 2004-11-30 2008-06-05 日本ケミファ株式会社 ペルオキシソーム増殖剤活性化受容体δの活性化剤
KR20070090192A (ko) 2004-12-18 2007-09-05 바이엘 헬스케어 아게 (5ｓ)-3-[(ｓ)-플루오로(4-트리플루오로메틸페닐)메틸]-5,6,7,8-테트라히드로퀴놀린-5-올 유도체 및 이의 ｃｅｔｐ억제제로서의 용도
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
WO2006067531A1 (en) 2004-12-24 2006-06-29 Prosidion Ltd G-protein coupled receptor (gpr116) agonists and use thereof for treating obesity and diabetes
EP1838706A1 (en) 2004-12-24 2007-10-03 Prosidion Limited G-protein coupled receptor agonists
DK1848430T3 (da) 2004-12-31 2017-11-06 Dr Reddys Laboratories Ltd Nye benzylamin-derivativer som cetp-inhibitors
DE102005000666B3 (de) 2005-01-04 2006-10-05 Sanofi-Aventis Deutschland Gmbh Sulfonylpyrrolidine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CN101141957A (zh) 2005-02-03 2008-03-12 Irm责任有限公司 作为ppar调节剂的化合物和组合物
WO2006086562A2 (en) 2005-02-09 2006-08-17 Microbia, Inc. Phenylazetidinone derivatives
FR2883000B1 (fr) 2005-03-14 2007-06-01 Merck Sante Soc Par Actions Si Derives de trifluoromethylbenzamide et leurs utilisations en therapeutique
WO2006102674A2 (en) 2005-03-24 2006-09-28 Microbia, Inc. Diphenylheterocycle cholesterol absorption inhibitors
AU2006236939A1 (en) 2005-04-13 2006-10-26 Merck Sharp & Dohme Corp. Niacin receptor agonists, compositions containing such compounds and methods of treatment
JP2008539255A (ja) 2005-04-26 2008-11-13 マイクロビア インコーポレーテッド 高コレステロール血症のための４−ビアリーリル−１−フェニルアゼチジン−２−オングルクロニド誘導体
WO2006121861A2 (en) 2005-05-05 2006-11-16 Microbia, Inc. Biphenylazetidinone cholesterol absorption inhibitors
JP2008539735A (ja) 2005-05-06 2008-11-20 バイエル・フアーマシユーチカルズ・コーポレーシヨン グルカゴン様ペプチド１（ｇｌｐ−１）受容体アンタゴニストおよびそれらの薬理学的使用方法
WO2006122186A2 (en) 2005-05-10 2006-11-16 Microbia, Inc. 1,4-diphenyl-3-hydroxyalkyl-2-azetidinone derivatives for treating hypercholestrolemia
JP2008540557A (ja) 2005-05-11 2008-11-20 マイクロビア インコーポレーテッド フェノール型４−ビフェニリルアゼチジン−２−オンの製造方法
CN101166545B (zh) 2005-05-13 2011-06-15 伊莱利利公司 Glp-1聚乙二醇化的化合物
US7723342B2 (en) 2005-05-17 2010-05-25 Schering Corporation Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
AU2006249905A1 (en) 2005-05-25 2006-11-30 Microbia, Inc. Processes for production of 4-(biphenylyl)azetidin-2-one phosphonic acids
US7696177B2 (en) 2005-06-15 2010-04-13 Merck Sharp & Dohme Corp. Anti-hypercholesterolemic compounds
UY29607A1 (es) 2005-06-20 2007-01-31 Astrazeneca Ab Compuestos quimicos
AR056866A1 (es) 2005-06-22 2007-10-31 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona, una formulacion farmaceutica y un proceso de preparacion del compuesto
AR054482A1 (es) 2005-06-22 2007-06-27 Astrazeneca Ab Derivados de azetidinona para el tratamiento de hiperlipidemias
AR057383A1 (es) 2005-06-22 2007-12-05 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
MY148538A (en) 2005-06-22 2013-04-30 Astrazeneca Ab Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
AR057380A1 (es) 2005-06-22 2007-11-28 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
US7067689B1 (en) * 2005-07-08 2006-06-27 Microbia, Inc. Process for production of pentahydroxyhexylcarbamoyl alkanoic acids
JP2007022943A (ja) 2005-07-13 2007-02-01 Dai Ichi Seiyaku Co Ltd スクアレン合成酵素阻害薬
DE102005033100B3 (de) 2005-07-15 2007-01-25 Sanofi-Aventis Deutschland Gmbh Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, diese Verbindung enthaltene Arzneimittel und Verfahren zu deren Herstellung
DE102005033099A1 (de) 2005-07-15 2007-01-18 Sanofi-Aventis Deutschland Gmbh Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindung enthaltende Arzneimittel und dessen Verwendung
WO2007015744A1 (en) 2005-07-21 2007-02-08 Incyte Corporation Disubstituted thienyl compounds and their use as pharmaceuticals
JP5112316B2 (ja) 2005-08-10 2013-01-09 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 選択的ｈｍ７４ａアゴニストとしてのキサンチン誘導体
GB0516462D0 (en) 2005-08-10 2005-09-14 Smithkline Beecham Corp Novel compounds
JP2009507791A (ja) 2005-08-29 2009-02-26 メルク エンド カムパニー インコーポレーテッド ナイアシン受容体アゴニスト、このような化合物を含有する組成物、および治療方法
EP1921074A1 (en) 2005-08-31 2008-05-14 Astellas Pharma Inc. Thiazole derivative
WO2007039172A1 (en) 2005-09-29 2007-04-12 Sanofi-Aventis Phenyl- and pyridyl-i, 2 , 4 -oxadiazolone derivatives with phenyl group, processes for their preparation and their use as pharmaceuticals
CA2624032A1 (en) 2005-09-30 2007-04-12 Merck & Co., Inc. Cholesteryl ester transfer protein inhibitors
DE102005055726A1 (de) * 2005-11-23 2007-08-30 Sanofi-Aventis Deutschland Gmbh Hydroxy-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US20080319221A1 (en) 2007-06-22 2008-12-25 Bernd Junker Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids
US20080319218A1 (en) * 2007-06-22 2008-12-25 Andreas Haubrich Processes for Making and Using Benzyl Pentahydroxyhexylcarbamoylundecanoate
WO2009112203A1 (de) * 2008-03-14 2009-09-17 Sanofi-Aventis Deutschland Gmbh Verfahren zur herstellung eines diphenylazetidinons

Also Published As

Publication number Publication date
EP2220040B1 (de) 2013-01-16
WO2009062619A1 (de) 2009-05-22
CL2008003358A1 (es) 2009-06-26
DE102007054497B3 (de) 2009-07-23
JP2011503127A (ja) 2011-01-27
EP2220040A1 (de) 2010-08-25
UY31469A1 (es) 2009-07-17
US8003636B2 (en) 2011-08-23
DE102007063671A1 (de) 2009-06-25
US20090203578A1 (en) 2009-08-13
TW200936566A (en) 2009-09-01
AR069305A1 (es) 2010-01-13
PE20091165A1 (es) 2009-08-31
PA8803701A1 (es) 2009-06-23

Similar Documents

Publication Publication Date Title
US8518875B2 (en) (Carboxylalkylenephenyl)phenyloxamides, method for the production thereof and use of same as a medicament
US8148375B2 (en) (Cyclopropylphenyl)phenyloxamides, method for the production thereof, and use of same as a medicament
US20110059910A1 (en) Novel aromatic fluoroglycoside derivatives, pharmaceuticals comprising said compounds and the use thereof
JP2010509252A (ja) 改善された特性を有する新規な１，４−ベンゾチエピン−１，１−ジオキシド誘導体、それらの製造方法、上記化合物を含有する薬物、及びそれらの使用
JP2010509380A (ja) シクロヘキシル基で置換された新規な１，４−ベンゾチエピン−１，１−ジオキシド誘導体、それらの製造方法、上記化合物を含有する薬物及びそれらの使用
CN103080073A (zh) (2-芳基氧基乙酰基氨基)苯基-丙酸衍生物、其制备方法及其作为药物的用途
US20090264402A1 (en) Novel diphenylazetidinone substituted by piperazine-1-sulfonic acid and having improved pharmacological properties
US8003636B2 (en) Certain crystalline diphenylazetidinone hydrates, pharmaceutical compositions thereof and methods for their use
EP2683705B1 (de) Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8785608B2 (en) Crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
US8809325B2 (en) Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
EP2683700B1 (de) Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828995B2 (en) Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8901114B2 (en) Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
MC MK et al. PHARMACEUTICALS COMPRISING THESE COMPOUNDS AND THEIR USE
WO2010066690A1 (en) A novel crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2010068601A1 (en) A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
TW201341349A (zh) ３－［４－（苯基胺基草醯基胺基）苯基］己－４－酸，其製備方法及其作為藥物之用途
WO2010000401A1 (de) Verwendung von substituierten pyridinoncarbonsäurederivaten zur herstellung von medikamenten zur behandlung der dislipidämie

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111031

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111031

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130709

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131001

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131028

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees